Cosmos Health (Cosmos Health) ROCE % : -26.84% (As of Sep. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Cosmos Health ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cosmos Health's annualized ROCE % for the quarter that ended in Sep. 2023 was -26.84%.

Cosmos Health ROCE % Historical Data

The historical data trend for Cosmos Health's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosmos Health ROCE % Chart

Cosmos Health Annual Data

Trend

Jul13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

Get a 7-Day Free Trial

153.78

-29.37

-27.63

Cosmos Health Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
ROCE %	Get a 7-Day Free Trial															-29.43	-131.59	-2.95	-5.27	-26.84

Cosmos Health ROCE % Calculation

Cosmos Health's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-9.09	/	( ( (49.429 - 29.928)	+	(68.039 - 21.749) )	/ 2 )
	=	-9.09	/	( (19.501	+	46.29)	/ 2 )
	=	-9.09	/	32.8955
	=	-27.63 %

Cosmos Health's ROCE % of for the quarter that ended in Sep. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	-13.056	/	( ( (68.592 - 20.232)	+	(71.525 - 22.585) )	/ 2 )
	=	-13.056	/	( ( 48.36	+	48.94 )	/ 2 )
	=	-13.056	/	48.65
	=	-26.84 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

Cosmos Health (NAS:COSM) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cosmos Health ROCE % Related Terms

Thank you for viewing the detailed overview of Cosmos Health's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cosmos Health (Cosmos Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Cosmos Health Inc (NAS:COSM) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

V67A:Germany

Address

141 West Jackson Boulevard, Suite 4236, Chicago, IL, USA, 60604

Website

https://www.cosmoshold.com

Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers.

Executives

Grigorios Siokas	10 percent owner	5 AG. GEORGIOU STR., PILEA, THESSALONIKI J3 TK57001
Suhel Bhutawala	director	141 WEST JACKSON BOULEVARD, SUITE 4236, CHICAGO IL 60604
Nikolaos Bardakis	officer: Chief Operating Officer	141 WEST JACKSON BOULEVARD, SUITE 4236, CHICAGO IL 60604
Manfred Ziegler	director	141 WEST JACKSON BOULEVARD, SUITE 4236, CHICAGO IL 60604
Anastasios Aslidis	director	11 CANTERBURY LANE, WATCHUNG NJ 07069
Pavlos Ignatiades	officer: Chief Operating Officer	KALAPATHAKI 5, PANORAMA, THESSALONIKI J3 55236
Georgios Terzis	officer: Chief Financial Officer	2 MELITOS STR., NEA SMIRNI, ATTICA J3 17121
Peter Goldstein	director	151 NORTH NOB HILL ROAD SUITE 321, FORT LAUDERDALE FL 33324
John James Hoidas	director	9301 S. HARLEM AVENUE, OAK LAWN, CHICAGO IL 60453
Dimitrios Goulielmos	director, 10 percent owner, officer: CEO	141 WEST JACKSON BLVD, SUITE 4236, CHICAGO IL 60604
Panagiotis Tolis	director, officer: Secretary	PERICLEOUS 50 STREET, ATHENS J3 15232
Panagiotis Drakopoulos	director, 10 percent owner, officer: CEO	200 SOUTH WACKER DRIVE, SUITE 300, CHICAGO IL 60606
Vasileios Mavrogiannis	director, 10 percent owner, officer: CFO	TERTSETI 23 STREET, KESARIANI J3 16122